"Crohn Disease/economics"[MAJR] - Search Results

Year	Number of Results
1990	1
1992	2
1997	1
1998	2
1999	2
2000	4
2001	1
2002	6
2003	4
2004	2
2006	1
2007	2
2008	8
2009	8
2010	5
2011	11
2012	19
2013	15
2014	11
2015	7
2016	10
2017	10
2018	8
2019	8
2020	23
2021	5
2024	0

1

The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.

Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, Kim SC, Lawton RC, Murphy SM, Regueiro M, Rubin DT, Engel-Nitz NM, Heller CA. Park KT, et al. Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10. doi: 10.1093/ibd/izz104. Inflamm Bowel Dis. 2020. PMID: 31112238 Free PMC article.

2

The cost-effectiveness of infliximab in Crohn's disease.

Smart C, Selinger CP. Smart C, et al. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):589-98. doi: 10.1586/14737167.2014.950235. Epub 2014 Aug 20. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 25138162 Review.

3

Financial Toxicity in Crohn's Disease.

Voit A, Cross RK, Bellavance E, Bafford AC. Voit A, et al. J Clin Gastroenterol. 2019 Nov/Dec;53(10):e438-e443. doi: 10.1097/MCG.0000000000001139. J Clin Gastroenterol. 2019. PMID: 30358642

4

Cost of illness of Crohn's disease.

Bodger K. Bodger K. Pharmacoeconomics. 2002;20(10):639-52. doi: 10.2165/00019053-200220100-00001. Pharmacoeconomics. 2002. PMID: 12162753 Review.

5

Advances in the management of Crohn's disease: economic and clinical potential of infliximab.

Hanauer SB, Cohen RD, Becker RV 3rd, Larson LR, Vreeland MG. Hanauer SB, et al. Clin Ther. 1998 Sep-Oct;20(5):1009-28. doi: 10.1016/s0149-2918(98)80082-9. Clin Ther. 1998. PMID: 9829451 Review.

6

Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.

Del Hoyo J, Nos P, Bastida G, Faubel R, Muñoz D, Garrido-Marín A, Valero-Pérez E, Bejar-Serrano S, Aguas M. Del Hoyo J, et al. J Med Internet Res. 2019 Sep 13;21(9):e15505. doi: 10.2196/15505. J Med Internet Res. 2019. PMID: 31538948 Free PMC article.

7

Cost-effectiveness of Crohn's disease post-operative care.

Wright EK, Kamm MA, Dr Cruz P, Hamilton AL, Ritchie KJ, Bell SJ, Brown SJ, Connell WR, Desmond PV, Liew D. Wright EK, et al. World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860. World J Gastroenterol. 2016. PMID: 27076772 Free PMC article. Clinical Trial.

8

Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.

Augustine JM, Lee JK, Armstrong EP. Augustine JM, et al. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):599-609. doi: 10.1586/14737167.2014.957680. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 25209304 Review.

9

Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses.

Marchetti M, Liberato NL. Marchetti M, et al. Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):815-24. doi: 10.1586/14737167.2014.957682. Epub 2014 Sep 27. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 25262931 Review.

10

Clinical economics review: medical management of inflammatory bowel disease.

Ward FM, Bodger K, Daly MJ, Heatley RV. Ward FM, et al. Aliment Pharmacol Ther. 1999 Jan;13(1):15-25. doi: 10.1046/j.1365-2036.1999.00437.x. Aliment Pharmacol Ther. 1999. PMID: 9892875 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

154 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year